Login to Your Account



Clinic roundup


Tuesday, April 29, 2014

Brainstorm Cell Therapeutics Inc., of New York and Petach Tikvah, Israel, said the FDA approved commencement of its phase II trial with Nurown in patients with amyotrophic lateral sclerosis (ALS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription